Parkinson's Disease Support Group
Parkinson's disease is a movement disorder often characterized by muscle rigidity, tremor, a slowing of physical movement, and in extreme cases, a loss of physical movement. The primary symptoms of Parkinsons are due to excessive muscle contraction, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the...
27th July 2014 - News release
NASAL DELIVERY OF PARKINSON'S DISEASE TREATMENT
Expert opinion on drug delivery [2014] 11 (6) : 827-842 (S.Md, S.Haque, M.Fazil, M. Kumar, S.Baboota, J.K.Sahni, J.Ali) Complete abstract
Researchers evaluated whether prepared nanoparticles would be able to target Parkinson's Disease treatments to the brain via the nasal route, thereby enhancing their bioavailability. They tested the method using an optimised nanoformulation of the dopamine agonist bromocriptine for direct nose-to-brain delivery.
The percentage accuracy observed for intra-day and inter-day batch samples was very high. Bromocriptine was found to be stable in all exposed conditions. Bromocriptine nanoparticles also showed greater retention into the nostrils for about four hours. Direct bromocriptine nanoparticle nose-to-brain transport was shown to then bypass the blood-brain barrier. Most importantly, bromocriptine nanoparticles administered nasally showed significantly high dopamine concentrations.
The researchers concluded that Nanoparticle drug delivery system could be potentially used as a nose-to-brain drug delivery carrier for improving the existing means of treating Parkinson's Disease. In order to refer to this article on its own click here
NASAL DELIVERY OF PARKINSON'S DISEASE TREATMENT
Expert opinion on drug delivery [2014] 11 (6) : 827-842 (S.Md, S.Haque, M.Fazil, M. Kumar, S.Baboota, J.K.Sahni, J.Ali) Complete abstract
Researchers evaluated whether prepared nanoparticles would be able to target Parkinson's Disease treatments to the brain via the nasal route, thereby enhancing their bioavailability. They tested the method using an optimised nanoformulation of the dopamine agonist bromocriptine for direct nose-to-brain delivery.
The percentage accuracy observed for intra-day and inter-day batch samples was very high. Bromocriptine was found to be stable in all exposed conditions. Bromocriptine nanoparticles also showed greater retention into the nostrils for about four hours. Direct bromocriptine nanoparticle nose-to-brain transport was shown to then bypass the blood-brain barrier. Most importantly, bromocriptine nanoparticles administered nasally showed significantly high dopamine concentrations.
The researchers concluded that Nanoparticle drug delivery system could be potentially used as a nose-to-brain drug delivery carrier for improving the existing means of treating Parkinson's Disease. In order to refer to this article on its own click here
This is wonderful news! It makes sense to take dopamine through the nose as it is a more direct route to the brain. Can you imagine? No longer would one have to wait an hour or more for the meds to kick in.
We might also be able to get a more pure form of dopamine or concentrate so we would not have to take so many pills with all the extra junk in them.
Thanks for posting this.
Madge
So glad this was good news for someone. The Novartis site sends up any PD updates as they are announced. This one seemed like one worth posting!
Annie